Table 3

Pharmacokinetics of COMT inhibitors nitecapone, entacapone, and tolcapone in healthy subjects after oral administration

	Entacapone^3-a		Nitecapone^3-b	Tolcapone^3-c
	100 mg	200 mg	100 mg	100 mg	200 mg
C _max(μg/ml)	1.1	1.8	2.6	4.6	5.7–6.3
T _max (h)	0.6	0.7	0.6	1.7	1.8
AUC_0–∞(h · μg/ml)	0.7	1.6	2.7	12.2	17.5–18.5
T _½β(h)	1.6	3.4	N.A.	2	1.8–2.1
Oral bioavailability (%)	32	36	56	N.A.	60

N.A., not available.
↵3-a Keränen et al., 1994.
↵3-b Pentikäinen et al., 1989.
↵3-c Dingemanse et al., 1995a; Jorga et al., 1998a.
Values are means.